Category: Prof. Erika Lietzan ⋅ Page 3

Professor Lietzan Receives ‘Best Lawyer’ honors

Professor Erika Lietzan has been named a “Best Lawyer in America”  in FDA Law and in Biotechnology and Life Sciences Law.  This marks the sixth year in a row for FDA law and the twelfth year in a row for biotechnology law.  The Best Lawyers honor is meant to identify the top 5 percent of practicing attorneys in the United…

Professor Lietzan Speaks at Food & Drug Law Institute’s Annual Conference

On May 4, Professor Erika Lietzan participated in the perennially popular closing session – on significant litigation in 2017 and cases to watch in 2018 – of the Food & Drug Law Institute’s annual conference.  FDLI is the primary professional association for specialists in food and drug law.  The annual meeting brought together more than 900 law professors, practicing lawyers,…

Professor Lietzan Featured on Webcast about New Uses for Established Drugs

On March 29, Professor Erika Lietzan was the featured speaker in a webcast from the Syracuse College of Law’s IP Tech Law Center.  She spoke with Shubha Ghosh about ensuring effective patent and regulatory exclusivity incentives for the development of new uses for already established drugs.  Her recent article on this topic, “Paper Promises for Drug Innovation” will be published…

Professor Lietzan Speaks About FDA Regulation of Direct-to-Consumer Genetic Testing

Professor Erika Lietzan spoke on March 16 at “Frontiers in Precision Medicine III: Will Personalized Medicine Improve Population Health?” –  a full day symposium hosted by the University of Utah S.J. Quinney School of Law, the Huntsman Cancer Institute at the University of Utah, and the School of Medicine at the University of Utah.  Professor Lietzan’s presentation focused on FDA…

Professor Lietzan Speaks at Conference about New Uses of Established Drugs

On February 8, Professor Erika Lietzan spoke at the conference, “Clinical Innovation: Fair and Effective Incentives for New Uses of Established Drugs,” convened in Washington, DC, by University College London (UCL) and the Georgetown University Law Center (GULC). This invitation-only conference gathered more than 40 experienced thought leaders — including scientists, industry executives, lawyers, law professors, business professors, judges, retired judges, and regulators, most with several decades of…

Professor Lietzan Presents Research Examining Impact of Pharmaceutical Regulation

In December, Professor Erika Lietzan spoke at a pharmaceutical law conference hosted by the CREDIMI, a center for research relating to markets and international investment, at the school of law at the Université de Bourgogne in Dijon, France. She presented her research examining the impact of pharmaceutical regulation on effective patent life and discussed its implications for restoration of patent…

Professor Lietzan Speaks on Panel at Supreme Court IP Review

Professor Erika Lietzan recently served as a panelist at the Supreme Court IP Review held at the Chicago-Kent College of Law. She discussed Sandoz, Inc. v. Amgen. Inc., a case decided by the Supreme Court last June. In October 2014, Amgen, a biopharmaceutical company which manufactures Neupogen, an innovative bone marrow stimulant, sued Sandoz, a biopharmaceutical company which manufactures Zarxio,…

Pan American Journal of Public Health Publishes Letter from Professor Lietzan

The Pan American Journal of Public Health published a letter from Professor Erika Lietzan, in which she responds to an article about Colombia’s pathways for approval of biosimilar biologics. A 2014 presidential decree in Colombia allowed for three pathways to market for biologics, and the earlier article, written by the country’s Minister of Health and Social Protection and his colleagues,…

Professor Lietzan Named Best Lawyer in FDA Law and Biotechnology Law

Professor Lietzan has again been named a “Best Lawyer in America” in both FDA Law and Biotechnology Law. This marks the fifth year in a row for FDA Law and the eleventh year in a row for Biotechnology Law. The Best Lawyers honor is meant to identify the top 5 percent of practicing attorneys in the United States, and it…

Erika Lietzan Featured on ‘The Week in Health Law’ Podcast

Professor Lietzan was recently a guest on “This Week in Health Law,” a commuting-length podcast that tackles thorny issues in health law and policy. She discussed her research on the relationship between drug innovation and incentives for innovation, and the conversation touched on large molecule drugs, biosimilars, data exclusivity and market exclusivity, patent protection, and her extensive empirical research on…